GoAI
Get started
SS Innovations International, Inc. logo

SS Innovations International, Inc.

SSII

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$3.585

−$0.025 · -0.69%

Aug 21, 4:00 PM ET

SSII company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

58

Fair Value

Momentum

32

Weakening

Sentiment

61

Bullish

Risk resilience

32

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

SS Innovations International, Inc., situated in Fort Lauderdale, Florida, focuses on the development of sophisticated robotic systems for surgical use. Their offerings encompass the SSI Mantra, a specialized surgical robot, and SSI Mudra, a suite of surgical instruments designed to facilitate various operations, including robotic cardiac surgery. The company also provides SSI Maya, a dedicated platform for robotic surgical interventions, along with OMNI 3D HD, which delivers a real-time, high-definition 3D perspective of the surgical field within the operating room.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Sudhir Prem Srivastava
Listed since
Oct 17, 2018
Employees
483

Market position

Day range

Current $3.585

52-week range

Current $3.585

Open
$3.57
Previous close
$3.61
Volume
62.23K
1.04× average
Average volume
59.59K
Average daily volume
Market cap
717.47M USD
Beta
0.67
Market reference 1
50-day average
$3.673
-2.40% below average
200-day average
$4.6406
-22.75% below average

Financials

Financial snapshot

Latest / TTM

Financial health

Altman Z-score
9.76
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends90%-85%-259%-433%Gross margin, FY2022: 33.57%Gross margin, FY2023: 12.13%Gross margin, FY2024: 40.93%Gross margin, FY2025: 46.00%Operating margin, FY2022: -389.44%Operating margin, FY2023: -351.52%Operating margin, FY2024: -91.90%Operating margin, FY2025: -19.29%Net margin, FY2022: -384.11%Net margin, FY2023: -356.17%Net margin, FY2024: -92.74%Net margin, FY2025: -28.55%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2022 33.57%. Gross margin FY2023 12.13%. Gross margin FY2024 40.93%. Gross margin FY2025 46.00%. Operating margin FY2022 -389.44%. Operating margin FY2023 -351.52%. Operating margin FY2024 -91.90%. Operating margin FY2025 -19.29%. Net margin FY2022 -384.11%. Net margin FY2023 -356.17%. Net margin FY2024 -92.74%. Net margin FY2025 -28.55%.

Income trends

Revenue

42.48M USD+105.74%

Operating income

−8.19M USD+56.82%

Net income

−12.13M USD+36.68%
Income trends across reported periods48.83M USD23.46M USD−1.91M USD−27.28M USDRevenue, FY2022: 1.46M USDRevenue, FY2023: 5.88M USDRevenue, FY2024: 20.65M USDRevenue, FY2025: 42.48M USDOperating income, FY2021: −1.41M USDOperating income, FY2022: −5.68M USDOperating income, FY2023: −20.67M USDOperating income, FY2024: −18.98M USDOperating income, FY2025: −8.19M USDNet income, FY2021: −1.48M USDNet income, FY2022: −5.6M USDNet income, FY2023: −20.94M USDNet income, FY2024: −19.15M USDNet income, FY2025: −12.13M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2022 1.46M USD. Revenue FY2023 5.88M USD. Revenue FY2024 20.65M USD. Revenue FY2025 42.48M USD. Operating income FY2021 −1.41M USD. Operating income FY2022 −5.68M USD. Operating income FY2023 −20.67M USD. Operating income FY2024 −18.98M USD. Operating income FY2025 −8.19M USD. Net income FY2021 −1.48M USD. Net income FY2022 −5.6M USD. Net income FY2023 −20.94M USD. Net income FY2024 −19.15M USD. Net income FY2025 −12.13M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue42.48M USD20.65M USD5.88M USD1.46M USD—
Cost of goods sold22.94M USD12.2M USD5.17M USD968.72K USD18.79K USD
Gross profit19.54M USD8.45M USD713.45K USD489.59K USD−18.79K USD
Research and development3.69M USD2.49M USD576.17K USD83.28K USD1K USD
Selling, general, and administrative22.98M USD24.5M USD20.81M USD6.09M USD1.39M USD
Operating expenses27.74M USD27.43M USD21.38M USD6.17M USD1.39M USD
Interest income1.14M USD798K USD129.76K USD239.73K USD118 USD
Interest expense1.11M USD973.24K USD523.36K USD162K USD—
Depreciation and amortization1.08M USD436.01K USD162.62K USD128.9K USD18.79K USD
Operating income−8.19M USD−18.98M USD−20.67M USD−5.68M USD−1.41M USD
Net income−12.13M USD−19.15M USD−20.94M USD−5.6M USD−1.48M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
0%
0 beats, 0 misses, 2 met estimates
Average EPS surprise
0.00%
2 comparable reports
Latest EPS result
-0.01
Estimate -0.01 · Met by 0.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0-0.03-0.05-0.08Q1 '25No estimateQ2 '25No estimateQ3 '25No estimateQ4 '25No estimateQ1 '26No estimateQ2 '26MetQ3 '26MetQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual -0.041, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 14, 2025: actual -0.03, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 7, 2025: actual -0.001, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Oct 28, 2025: actual -0.02, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 10, 2026: actual -0.01, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 13, 2026: actual -0.02, estimate -0.02, surprise 0.00%, Met estimate. Q3 2026, reported Aug 13, 2026: actual -0.01, estimate -0.01, surprise 0.00%, Met estimate. Q4 2026, reported Oct 27, 2026: actual —, estimate -0.01, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates15.79M11.98M8.17M4.35MQ1 '25No estimateQ2 '25No estimateQ3 '25No estimateQ4 '25No estimateQ1 '26No estimateQ2 '26MetQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual 5.62M USD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 14, 2025: actual 5.12M USD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 7, 2025: actual 10M USD, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Oct 28, 2025: actual 12.83M USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 10, 2026: actual 14.53M USD, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 13, 2026: actual 11M USD, estimate 11M USD, surprise 0.00%, Met estimate. Q3 2026, reported Aug 13, 2026: actual 13.94M USD, estimate 12M USD, surprise +16.16%, Beat. Q4 2026, reported Oct 27, 2026: actual —, estimate 15M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$7.00

95.26% upside
Past 12 months12-month forecast

Price history unavailable

High $7.00Average $7.00Low $7.00

SSII news

globenewswire.com

SS Innovations Reports Second Quarter 2026 Financial Results

Record quarterly revenue driven by continuing strong growth in SSi Mantra unit sales Record quarterly revenue driven by continuing strong growth in SSi Mantra unit sales

Read source
globenewswire.com

SS Innovations To Showcase the SSi Mantra Surgical Robotic System at SRS 2026

Company's advanced surgical robotic system will be on display, spotlighted in multiple breakout sessions, and featured in a kidney telesurgery to be broadcast live at the premier industry event Company's advanced…

Read source
globenewswire.com

SS Innovations Appoints Sarah M. Romano as Chief Financial Officer

Veteran medtech finance executive brings extensive public company and capital markets experience to support the Company's next phase of global growth Veteran medtech finance executive brings extensive public company and…

Read source
globenewswire.com

SS Innovations Subsidiary SSICRS Graduates Inaugural Cardiac Robotic Surgery Training Class

New course empowers healthcare professionals through expert instruction and hands-on learning New course empowers healthcare professionals through expert instruction and hands-on learning

Read source
globenewswire.com

IBN Initiates Coverage of SS Innovations International, Inc.

AUSTIN, Texas, July 07, 2026 (GLOBE NEWSWIRE) -- via IBN – SS Innovations International, Inc. (NASDAQ: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and…

Read source
globenewswire.com

SS Innovations Named Outstanding Company Winner at the 2026 Surgical Robotics Industry Awards

FORT LAUDERDALE, Fla. , June 30, 2026 (GLOBE NEWSWIRE) -- via IBN -- SS Innovations International, Inc. (the "Company" or "SS Innovations") (NASDAQ: SSII), a developer of innovative surgical robotic technologies…

Read source

Corporate actions

Corporate action history

Stock split

Effective Apr 17, 2023

1:10

SSII peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding SSII

Funds reporting this stock among their holdings, ordered by reported position size.

Inspire Small/Mid Cap ETF logoInspire Small/Mid Cap ETFISMD
Market value
691.16K
Weight
0.20%
AUM
349.35M USD
Expense ratio
0.53%
Price / 1D
$49.57+0.36%
State Street SPDR S&P Emerging Markets Small Cap ETF logoState Street SPDR S&P Emerging Markets Small Cap ETFEWX
Market value
51.33K
Weight
0.01%
AUM
685.65M USD
Expense ratio
0.65%
Price / 1D
$72.22+0.25%

Continue in GoAI

Research SSII

research.disclaimer